Rebus Biosystems Inc. has closed a $20 million series B fundraising round. The financing round was led by Illumina Ventures with participation by Lifecore Partners, Ncore Ventures, Xolon Invest, Ctk Investments, Ray Co. Ltd., Seegene Medical Foundation, Labgenomics Co. Ltd. and Timefolio Asset Management. Rebus builds spatial omics tools, assays and platforms. The company plans to use the new funding to support commercialization of its spatial omics solution and expansion of its marketing, sales, research, and product development teams, said Rebus CEO Paul Sargeant. Rebus plans to launch its automated, standalone Rebus Biosystems instrument and optimized assay kits for spatial transcriptomics early in 2021.
HONG KONG – D3 Bio Inc. is the new kid on the biopharma block in Shanghai, kicking off with a $200 million series A financing backed by some of Asia’s most prominent venture capital firms.
DUBLIN – Synox Therapeutics Ltd., a spin-out from Celleron Therapeutics Ltd., has raised €37 million (US$43.7 million) in a series A round to conduct a pivotal trial of emactuzumab, an antibody its parent company in-licensed from Roche Holding AG in August.
DUBLIN – Health care investor Syncona Ltd. has founded a new startup, Purespring Therapeutics Ltd., to take gene therapy into the kidney. It is committing £45 million (US$59.6 million) in series A funding, which will support the build-out of the new company and take at least one program into the clinic.
Biopharmas raising money in public or private financings, including: 4D Molecular, Beyondspring, Briacell, Elevation, Emergex, Evommune, Five Prime, Gan & Lee, Hemogenyx, Keros, Kodiak, Oblique, Oncternal, Oric, Pharvaris, Population Health Investment, Qiming, Scopus, Umoja, Xiaomi.
RSS
